BRCA1 and ovarian cancer: Several other reports have, in the context of BRCA1−/− ovarian cancers and their sensitivity to small molecule PARP inhibitors, presented preclinical and clinical evidence that the concept of synthetic lethality which defines a condition whereby two mutations, each with viable phenotypes, produce a lethal phenotype when they are combined can thus be exploited as a molecular-targeted strategy [133, 135, 143–147].